Designing the First Clinical Trial Targeting Aging
This piece outlines a conceptual framework for how a pivotal clinical trial targeting aging could be structured. It explores challenges in endpoint selection, regulatory alignment, and trial economics—ultimately proposing a multimorbidity-prevention design as the most viable path forward. A sample size calculator is included to help evaluate feasibility across different therapies. The goal: make aging drugs trialable, reimbursable, and real.

Norn Group’s mission is to maximize the probability that by 2060 we have interventions that will let a 60 year old live for another 60 years without a decline in health and function.
But how? Read about our approach, why aging should be treated as the root cause of chronic disease, why current tools are not enough, and how targeted investment in biomarkers, trial infrastructure, and interdisciplinary talent can accelerate progress of our Mission.